NASDAQ
AKTX

Akari Therapeutics PLC

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Akari Therapeutics PLC Stock Price

Vitals

Today's Low:
$0.4490
Today's High:
$0.5201
Open Price:
$0.4710
52W Low:
$0.381
52W High:
$1.7
Prev. Close:
$0.4710
Volume:
151629

Company Statistics

Market Cap.:
$0.029 billion
Book Value:
0.14
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-141.9%
Return on Equity TTM:
-365.1%

Company Profile

Akari Therapeutics PLC had its IPO on 2015-09-21 under the ticker symbol AKTX.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Akari Therapeutics PLC has a staff strength of 0 employees.

Stock update

Shares of Akari Therapeutics PLC opened at $0.47 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $0.45 - $0.52, and closed at $0.49.

This is a +4.03% increase from the previous day's closing price.

A total volume of 151,629 shares were traded at the close of the day’s session.

In the last one week, shares of Akari Therapeutics PLC have increased by 0%.

Akari Therapeutics PLC's Key Ratios

Akari Therapeutics PLC has a market cap of $0.029 billion, indicating a price to book ratio of 3.42 and a price to sales ratio of -.

In the last 12-months Akari Therapeutics PLC’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.018 billion. The EBITDA ratio measures Akari Therapeutics PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Akari Therapeutics PLC’s operating margin was 0% while its return on assets stood at -141.9% with a return of equity of -365.1%.

In Q2, Akari Therapeutics PLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Akari Therapeutics PLC’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
0

Its diluted EPS in the last 12-months stands at $-0.406 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Akari Therapeutics PLC’s profitability.

Akari Therapeutics PLC stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of -1.105. Its price to sales ratio in the trailing 12-months stood at -.

Akari Therapeutics PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Akari Therapeutics PLC ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Akari Therapeutics PLC ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Akari Therapeutics PLC’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Akari Therapeutics PLC's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Akari Therapeutics PLC paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$0.49
52-Week High
$1.7
52-Week Low
$0.381
Analyst Target Price
$4

Akari Therapeutics PLC stock is currently trading at $0.49 per share. It touched a 52-week high of $1.7 and a 52-week low of $1.7. Analysts tracking the stock have a 12-month average target price of $4.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Akari Therapeutics PLC

The stock symbol (also called stock or share ticker) of Akari Therapeutics PLC is AKTX

The IPO of Akari Therapeutics PLC took place on 2015-09-21

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$0.94
-0
-0.46%
$6.02
-0.26
-4.14%
$24.49
-1.29
-5%
$12.97
-0.23
-1.71%
$49.62
-1.07
-2.11%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.

Address

24 WEST 40TH STREET, 8TH FLOOR, NEW YORK, NY, US